News
Investigators systematically evaluate the efficacy differences of existing treatment regimens for IgA nephropathy.
4d
Clinical Trials Arena on MSNPurespring’s Phase I/II trial for IgA nephropathy approved in UK
Purespring Therapeutics has received approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead ...
Q2 2025 Management View Eric M. Dube, President and CEO, described Q2 2025 as "a standout for Travere, a reflection of strong ...
EP: 2. Introduction to IgA Nephropathy EP: 3. Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines EP: 4. Diagnosing IgA Nephropathy ...
Panelists discuss how current immunoglobulin A (IgA) nephropathy treatments primarily target downstream inflammatory pathways of the 4-hit cascade, with emerging therapies now beginning to address ...
For example, previous studies showed that IgA1 immunodeposits in IgA nephropathy are enriched for galactose-deficient IgA1, likely originating from the IgA1-IgG complexes formed in the circulation.
In this video, Ali Poyan Mehr, MD, Regional Director of the Glomerular Disease Program at Kaiser Permanente Northern California, discusses the major risk factors for IgA nephropathy.
The autoimmune kidney disease known as IgA nephropathy or Immunoglobulin A nephropathy (IgAN) is caused by immune cells that have the protein CD38 on their surface. An experimental anti-CD38 ...
DelveInsight’s IgA nephropathy pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for IgA nephropathy treatment.New York, USA, Dec. 14, 2022 ...
Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...
IgA nephropathy is the most common cause of primary glomerulonephritis in the world. Although progression of the disease is variable, it is typically very slow. There are several clinical and ...
The relationship between IgA nephropathy and sarcoidosis remains interesting but controversial. Both conditions are systemic disorders with unknown cause. Familial clustering has been reported in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results